Acquired resistance to androgen receptor (AR)-targeted therapies compels the development of novel treatment strategies for castration-resistant prostate cancer (CRPC). Here, we report a profound effect of endostatin on prostate cancer cells by efficient intracellular trafficking, direct interaction with AR, reduction of nuclear AR level, and down-regulation of AR-target gene transcription. Structural modeling followed by functional analyses further revealed that phenylalanine-rich α1-helix in endostatin-which shares structural similarity with noncanonical nuclear receptor box in ARantagonizes AR transcriptional activity by occupying the activation function (AF)-2 binding interface for coactivators and N-terminal AR AF-1. Together, our data suggest that endostatin can be recognized as an endogenous AR inhibitor that impairs receptor function through protein-protein interaction. These findings provide new insights into endostatin whose antitumor effect is not limited to inhibiting angiogenesis, but can be translated to suppressing AR-mediated disease progression in CRPC.
Acquired resistance to androgen receptor (AR)-targeted therapies compels the development of novel treatment strategies for castration-resistant prostate cancer (CRPC). Here, we report a profound effect of endostatin on prostate cancer cells by efficient intracellular trafficking, direct interaction with AR, reduction of nuclear AR level, and down-regulation of AR-target gene transcription. Structural modeling followed by functional analyses further revealed that phenylalanine-rich α1-helix in endostatin-which shares structural similarity with noncanonical nuclear receptor box in ARantagonizes AR transcriptional activity by occupying the activation function (AF)-2 binding interface for coactivators and N-terminal AR AF-1. Together, our data suggest that endostatin can be recognized as an endogenous AR inhibitor that impairs receptor function through protein-protein interaction. These findings provide new insights into endostatin whose antitumor effect is not limited to inhibiting angiogenesis, but can be translated to suppressing AR-mediated disease progression in CRPC.
endostatin | androgen receptor | prostate cancer | chemoresistance A bnormalities in the androgen-androgen receptor (AR) axis have been well recognized in promoting prostate cancer (PCa) growth and metastasis. Although the current therapies using androgen deprivation and antiandrogens show transient tumor regression, the tumor relapse to castration-refractory metastatic stage remains a big challenge (1) . The molecular basis of continued AR function in castration-resistant PCa (CRPC) has shifted the paradigm in our understanding of androgen-independent mechanisms, leading to therapeutic strategies directly targeting the receptor (2, 3) . Despite modest improvements in AR-targeted therapies, tumor relapse ensues with up-regulated AR expression and transcriptional activation of downstream AR-target genes (4, 5) . Recent studies also identified that a somatic mutation in AR ligand-binding domain (LBD; F876L) sustains AR function by converting antagonistic actions of the second-generation antiandrogens, such as enzalutamide and ARN-509, to agonist response (1, 6) . Thus, discovery of potent AR antagonists that can overcome AR-associated drug resistance remains imminent for clinical management of CRPC.
Endostatin (ES) is a 20-kDa proteolytic fragment of a noncollagenous domain (NC-1) in collagen type XVIII (7) . As an endogenous antiangiogenic protein, ES inhibits endothelial cell proliferation and tube formation (8, 9) . Since Judah Folkman's laboratory first identified ES (10, 11) , anticancer effects of ES have been extensively studied in both tumors and tumor-associated endothelia (8, (12) (13) (14) . In addition, studies with recombinant human ES fused with Zinc-binding peptide (ZBP-endostatin; Endostar) showed clinical benefit in patients with non-small-cell lung cancer (NSCLC) (11) . Recently, we showed that systemically stable levels of ES by vector-mediated gene transfer in vivo significantly delayed tumor growth in the transgenic adenocarcinoma of mouse prostate model (15) .
AR is a 120-kDa protein, composed of an N-terminal domain (NTD), a DNA binding domain (DBD), a hinge domain, and a C-terminal LBD. Like other nuclear receptors (NRs), AR is a transcription factor regulating target-gene expression in a liganddependent manner (2, 16) . Cognate ligand binding induces conformational changes predominantly in helix 12 of AR LBD, which enhances transcriptional activity by forming a liganddependent AF-2 binding interface for coactivators (17) . Wilson and colleagues demonstrated that the interdomain interaction between AF-1 in NTD and AF-2 in LBD (N/C interaction) leads to AR stabilization and slower ligand dissociation (18, 19) .
Functional activity of AR largely depends on AF-2 that accommodates the binding of various AR coactivators by recognizing specific sequence motifs, called NR box. Among NRs, AR is known to exhibit the binding preference to noncanonical NR box, containing FXXLF, FXXFF, and WXXLF motifs (20, 21) . In addition to coactivators, AR NTD has two AF-2-binding helical segments with FXXLF (residues [23] [24] [25] [26] [27] and WXXLF (residues 435-439) motifs. Interestingly, such binding motifs are also observed in ES α1-helix (F31-F34) and α2-helix (W83-F87), respectively (22, 23) . The similarities both in the sequence and structure between the helical motifs of ES and AR prompted us to study whether ES can mimic the structural basis of AR-NTD or coactivator binding to AR LBD. In line with our previous study showing the inhibitory effect of ES on PCa tumorigenesis, here, we provide direct evidence, for the first time, to our knowledge, that ES is a novel antagonist of AR function in PCa cells. The present study demonstrates that a direct molecular interaction of ES with AR disrupts AR-target gene transcription, leading to PCa growth inhibition.
Significance
Despite the development of second-generation androgen receptor (AR)-targeted therapies for castration-resistant prostate cancer (CRPC), the effects are only modest, compelling the need for novel therapy combinations that can maximize the antitumor effects of new-generation chemotherapies with minimal acquired resistance, attributed to AR modifications. The present study identified that endostatin (ES), known for its antiangiogenic properties on tumor vasculature, exerts a profound antiproliferative effect on AR-positive human PCa cells. By a systematic approach involving a combination of in situ, cell-free, yeast-two hybrid, structural modeling, and mutagenesis studies, we determined that intracellular trafficking of ES in AR-positive PCa cells leads to a direct interaction with AR in the cytosol, affecting the transcriptional activation of AR target genes. Results ES Targets AR Function in PCa Cells. To characterize the mechanism of action of ES on PCa cells, recombinant human ES was produced to homogeneity. Limitations in the production of ES in a soluble form, due to the presence of two disulfide bonds (11, 22) and complexities in refolding steps (8, 24, 25) , were overcome by using the Origami B(DE3) Escherichia coli strain. The expression system with glutathione reductase (gor) and thioredoxin reductase (trxB) mutations resulted in a high yield of soluble ES without requiring a refolding process (Fig. S1 A and B) . Recombinant ES with a C-terminal His-tag and the N-terminal heparin-binding site, formed by 11 arginines, enabled the efficient protein purification using nickel-affinity and heparin-agarose columns, respectively (Fig. S1C) . The biological activity of the purified recombinant ES was verified on human umbilical vein endothelial cells (Fig. S1E) .
To determine whether antitumor effects of ES are directly attributed to targeting AR function, both AR-positive (LNCaP and C4-2B) and AR-negative (PC3 and DU145) human PCa cells were included in the experiments (Fig. S2A ). Our study indicated that ES demonstrated a dose-dependent growth inhibition preferentially on AR-positive PCa cells (Fig. 1A ). Upon treatment with 1 μM ES for 72 h, the growth of LNCaP and C4-2B cells significantly decreased to 60.3% (±7.0) and 66.2% (±5.9), respectively (P < 0.05) (Fig. 1A and Fig. S2B ). Furthermore, the invasiveness of ES-treated LNCaP cells decreased to 61.4% (±2.98) (Fig. S2C) . Like other endogenous antiangiogenic factors, ES is known to induce apoptosis of endothelial cells through binding to and functionally disrupting cell-surface receptors (i.e., integrins) (26, 27) . In line with our previous study (28) , ES treatment also induced apoptosis in LNCaP cells by showing the activation of caspase-3 (Fig. S2D) . However, such antiproliferative effects were not observed in AR-negative PC-3 and DU145 cells, suggesting in part that the molecular action of ES involves targeting of AR-mediated cellular event(s).
To test the effect of ES on downstream AR-target gene expression, the levels of prostate-specific antigen (PSA), transmembrane protease serine 2 (TMPRSS2), and prostatic acid phosphatase (ACPP) were examined as surrogates. Immunocytochemistry indicated that the levels of PSA and TMPRSS2 were substantially decreased in ES-treated LNCaP cells (Fig. 1B and Fig. S3 ). Quantitative mRNA and protein analyses further confirmed down-regulation of PSA and TMPRSS2 expression and up-regulation of AR-repressed ACPP expression ( Fig. 1 C and D) . Such changes in the AR-target gene expression profile were similarly observed in another AR-positive and androgen-responsive cell upon ES treatment (Fig. S4) , indicating that ES impairs AR transcriptional activity in AR-positive PCa cells.
Intracellular Trafficking of ES Reduces the Level of Nuclear AR. Next, we characterized the possible molecular mechanism of how ES disrupts AR function. When LNCaP cells were treated with recombinant ES, it was interesting to note that the majority of ES was detected in the cytoplasm. Both immunocytochemistry and subcellular fractionation analysis confirmed intracellular trafficking of ES by showing an augmentation of ES in the cytoplasmic fraction. In AR-negative PC3 cells, however, ES internalization was observed to a lesser extent ( Fig. 2 A and B) . This finding prompted us to further examine whether internalized ES could alter AR localization and function in situ. When compared to nontreated LNCaP cells, we found that the level of AR in the nucleus was significantly decreased by 70% (P < 0.05) upon ES treatment (Fig. 2C ). In addition, immunofluorescence staining and quantitative protein analysis indicated an 86.2% decrease in total AR levels (P < 0.01) in ES-treated LNCaP cells ( Fig. 2 D and E) .
These observations raised a question of whether the internalized ES could induce AR degradation. Because 5α-dihydrotestosterone (DHT) binding to AR LBD is known to stabilize AR structure and function (3, 29) , we speculated that the internalized ES may interfere with the ligand binding to AR LBD. However, diminution of DHT in culture had no influence on growth inhibition exerted by ES treatment (Fig. S2E) . Furthermore, a similar level of growth inhibition was observed in ARpositive androgen-independent C4-2B cells (Fig. 1A) , suggesting that the mechanism by which ES affects AR stability may not require perturbation of ligand binding to AR LBD. Secondly, ligand-dependent N/C interdomain interaction is known to stabilize the structural integrity of AR (18) . Thus, it was conceivable that interaction of internalized ES with either AR NTD or LBD may have interrupted N/C interaction, thereby disrupting stability of the receptor. To test this hypothesis, it was crucial for us to investigate whether ES directly binds to AR. To determine the effect of ES on AR-target gene transcription and translation, LNCaP cells were grown on chamber slides in the presence or absence of 1 μM ES and stained by using anti-PSA and -TMPRSS2 antibodies, followed by Alexa 488-and 594-labeled secondary antibodies, respectively (B). Nuclei were stained with DAPI (see also Fig. S3 ). From replicate experiments, total cell lysate and RNA were isolated, and the protein and mRNA expression levels of PSA, TMPRSS2, and ACPP were determined by real-time RT-PCR (C) and immunoblotting (D), respectively (see also Fig. S4 ). All results are expressed as mean ± SEM. *P < 0.05; **P < 0.01 vs. control.
LNCaP cells that contained full-length AR, followed by immunoprecipitation using anti-ES antibody. Results indicated that AR was coimmunoprecipitated with ES (Fig. 3A) . The ES-AR complex was also purified by pull-down of His-tagged ES using nickel-affinity chromatography (Fig. 3B ). Protein analysis of the bound fraction showed that AR was coeluted with ES. The equivalent levels of β-actin in the input lysate and unbound fractions also confirmed predominant AR binding to ES, with a negligible level of free AR (Fig. 3B) . The pull-down fraction was further analyzed by native-polyacrylamide gel electrophoresis (native-PAGE). In nondenaturing condition, AR with acidic isoelectric point (p I = 6.1) was allowed to migrate into the native-gel at basic pH. In contrast, because of the pI (9.3) being above the pH (8.3) of Tris/glycine gel running buffer, ES did not migrate unless ES formed a complex with AR (Fig. S5) . When the pull-down fraction was analyzed on native-PAGE followed by immunoblotting, both ES and AR were detected in the same band, indicating the formation of ES-AR complex (Fig. 3C) . In order to demonstrate unequivocally that ES binding to AR was due to a direct interaction, we performed yeast-two hybridization assay. For this experiment, ES was expressed as a protein fused with a DBD (LexA) as a bait protein, and AR was fused with a transcriptional activation domain (AD) as a prey (Fig. 3D) . The ES-LexA and AR-AD fusion proteins were coexpressed in the EGY48 yeast cells where the binding site for LexA operator was located upstream of a LEU2 and LacZ reporter genes. The results confirmed that transformed cells containing only ES-LexA or AR-AD gene failed to grow in leucine-dropout medium, indicating that overexpression of either bait or prey protein by itself did not activate downstream LEU2 reporter gene transcription (Fig. 3E) ( Fig. 3E) . These results indicated that transcription of both LEU2 and LacZ reporter genes was triggered by the bait-trap protein interaction, confirming a direct interaction between ES and AR. In addition, because our binding experiments were carried out particularly in the presence of 10 nm DHT, it is possible that ES may target AR at the ligand-bound active conformation. To prove it experimentally, a pull-down assay was carried out in a similar manner, analyzing the reaction of ES with recombinant AR LBD. Results indicated that the LBD of AR is essentially involved in interaction with ES (Fig. 4A) .
Structural Analysis on Putative ES-Binding Site in AR. Molecular association of ES with AR in conjunction with its mechanism of action related to AR antagonism led us to characterize the structural basis of this protein-protein interaction. Our structural analysis showed that potential interaction may occur between the positively charged cluster (R24, R27, and R139) followed by the ES α1-helix and the negatively charged cluster (E709, E873, and E897) near the AR AF-2 coactivator binding interface (Fig. 4B) . Interestingly, we found that the α1-helix (R27-R38) and α2-helix (W83-F87) resemble the sequences of two α-helices in AR NTD that contain the FXXLF (R20-R31) and WXXLF (W435-F439) motifs, respectively (Fig.  4C) . However, only α1-helix contains the key aromatic residues that are accessible for the surface interaction with AR LBD (Fig. S6A) .
Based on the structure and sequence homology between the ES α1-helix and AR AF-1 helix, we generated a structural model of the ES/AR LBD complex, confining the surface contact of ES α1-helix to the AF-2 coactivator binding cleft in AR LBD ( Fig.  4D and Fig. S6 ). Despite the simple superposition of ES α1-helix in human ES structure [Protein Data Bank (PDB) ID code 1BNL] over the FXXLF helical peptide bound to AR AF-2 (PDB ID code 1XOW), it yielded a model of ES/AR LBD complex with minimal clashes between side chains (Fig. S6B) . Our model showed that ES α1-helix can mimic the FXXLF-motif binding to AR AF-2 by showing the side chains of Phe-31 and -34 in the ES helix faced to the hydrophobic core of the AF-2 binding cleft (Fig. 4D) . However, because the model was built by rigid body movement, residues Arg-27 and -38 that bracket the ES α1-helix are responsible for side-chain clashes with AR AF-2. With regard to this interpretation, it is interesting to note that the known AR AF-1 motif (R20-R31) from the complex structure with AR LBD would also position Arg-20 and -31 around this AF-2 interaction site (17) . These findings suggested that either rigid docking of ES helix to the AR LBD or cocrystal structure of AR LBD coupled with small peptides is limited by the inability to predict induced fit, and therefore some conformational flexibility may be necessary for the AR AF-2 site to accommodate either AF-1 or ES binding.
To validate the structural prediction that ES and AR NTD (or AR coactivators) may compete for AR AF-2, a peptide inhibition assay was performed. The AR20-30 peptide of AR NTD (residues 20-30) containing an FXXLF motif was used to mask the binding cleft of AF-2 in AR LBD (Fig. 4C) . Based on prior studies that suggested this peptide binds with a K D value of 1.2 μM to the AR LBD (21), peptide concentrations of 0.1-10 μM were tested in the experiment. We found that preincubation with 0.1-10 μM AR20-30 significantly reduced AR-LBD interaction with ES, resulting in >70-80% loss of binding to ES (Fig. 4E) . Such inhibition by the peptide masking supported our model of ES interaction at the AF-2 coactivator binding interface in LBD. Interestingly, the binding of full-length AR to ES was decreased only by 40-50% at higher concentrations of peptide (Fig. 4E) , suggesting in part that ES may also possess additional minor binding interface for another region of AR.
Phe-31 and -34 in ES Helix Play an Important Role in AR Binding.
Structural modeling and the peptide inhibition studies suggested that putative ES-binding site includes AR AF-2, which provides a binding platform for phenylalanine-rich ES α1-helix. Based on this model prediction, we further validated whether Phe-31 and -34 in the ES helix are critical for AR binding. For binding experiments, mutant forms of ES were generated by single amino acid substitution at Phe-31 and -34 to alanines (Fig. 5A and Table S1), and the ES antibody-recognizing amino acid residues 1-12 present in both wild-type and created mutant forms-was used for quantitative protein analysis. Compared with wild-type ES, bound After the peptide inhibition, ES was applied to reaction mixture and incubated for additional 6-8 h. The levels of AR bound to ES were analyzed by His-tag pulldown assay. The interaction inhibited by the peptide is presented as a relative value (mean ± SEM) of control (100%) from two independent experiments. *P < 0.05; **P < 0.01 vs. control. Peptide inhibition on AR binding to ES indicates that the ES-binding interface overlaps with AR AF-2.
AR was reduced by 83.9% and 89.0% in the reactions with ES F31A and ES F34A , respectively (P < 0.01; Fig. 5B ). In line with the result from pull-down assay, analysis of the ES-AR complex on a native gel also indicated 81.7% and 79.7% lower AR-binding abilities of ES F31A and ES F34A , respectively (P < 0.01; Fig. 5C ). In addition, size-exclusion chromatography analysis exhibited coelution of AR with wild-type ES, whereas mutant forms of ES failed to form a complex with AR by showing peak separations between AR and mutated ES in the chromatogram (Fig. 5D) . These results clearly indicated that ES binding to AR was significantly affected by substitution of aromatic side chains in the ES helix, suggesting that Phe-31 and -34 in the ES helix play an important role in AR binding. In accordance with binding assays, treatment with ES F31A or ES F34 showed no significant growth inhibition of AR-positive LNCaP and C4-2B cells (Fig. 5E) . These results provide direct evidence that the antiproliferative effect of ES is contributed by antagonistic action of ES on AR function via protein-protein interaction.
Discussion
Recent understanding of the role of AR in acquired resistance to antiandrogens among patients with CRPC compels a need to develop novel therapeutics capable of suppressing AR-associated tumor progression (2, 3) . Particularly, a missense mutation (F876L) in the AR ligand-binding site has been reported to cause resistance to enzalutamide through an antagonist-to-agonist switch (1, 6, 30) , indicating limitations in the use of small-molecule inhibitors for effective disruption of AR function. The functional activity of AR largely depends on ligand-dependent conformational change in AF-2 that accommodates coactivator binding. Therefore, instead of targeting the ligand-binding site, identifying biologically driven macromolecular inhibitors that fully occupy the AR AF-2 can be a viable alternative to current therapies.
In this context, the present study identified, to our knowledge, for the first time that ES directly binds to AR. Such a proteinprotein interaction interrupts AR nuclear transport and transcriptional activation of downstream AR-target genes, thereby attenuating the AR-associated malignant phenotype. In line with experimental data, model-based functional studies on the ES/AR LBD complex confirmed that the putative binding site for ES overlaps with the AR AF-2 coactivator binding interface. Given the distinct binding preference of AR AF-2 for noncanonical NR box with bulky aromatic residues (20, 21) , our structural analysis indicated a striking feature that ES contains α1-helix (R27-R38) and α2-helix (W83-F87) with amino acid sequences resembling the FXXLF and WXXLF motifs in the AR NTD (R20-R31 and W435-F439), respectively. Such a high sequence homology between the helices in ES and AR NTD suggests that ES can modulate AR function by mimicking the mode of coactivator binding or interaction between AR AF-1 with AF-2 interdomains. In agreement with the structural speculation, masking the AR AF-2 by using the synthetic peptide of AR AF-1 (R20-V30) significantly reduced the interaction of ES with AR LBD. Therefore, the molecular action of ES inhibiting AR transactivation may underlie the interruption of the AR N/C interaction as well as coactivator binding by occupying the AR AF-2.
Our study further confirms that the aromatic residues in ES α1-helix play a crucial role in AR binding. A site-directed mutagenesis study verified that ES interaction with AR was significantly reduced by the replacement of Phe-31 and -34 with alanines. The resultant decrease in AR binding substantially abolished the antagonistic action of ES on AR-mediated PCa cell growth, suggesting that the overall antiproliferative effect of ES on PCa cells is mainly attributed to the disruption of AR function via protein-protein interactions.
High sequence homology between ES α2-helix and the WXXLF motif in AR NTD also set our sights on Folkman's initial study harnessing an insoluble form of ES. This study demonstrated that delivery of insoluble ES directly into the xenograft tumors of Lewis lung carcinoma (LLC) exerted a profound antitumor effect, although the underlying mechanism remained unclear (8) . Although aromatic side chains of Trp-83, Leu-86, and Phe-87 in α2-helix are embedded in the hydrophobic core (Fig. S6A) , it is conceivable that insoluble ES, presumably due to lack of a proper folding, enables the bulky side chains of α2-helix (WXXLF) to be exposed for binding to AR AF-2. Indeed, disruption of ES folding, either by acid-induced unfolding or mutations on disulfide bonds, has been reported to increase α-helical content, suggesting that unfolded ES retains intrinsic α-helical secondary structures (31, 32) . Another interesting aspect of the earlier studies is that satisfactory outcomes were predominantly reported when ES was tested in patients and animal models with lung cancer. Recent studies using recombinant ES also showed the strongest response in LLC and NSCLC (11) (12) (13) . In this respect, it is noteworthy that elevated AR expression in the lung has been implicated in promoting the tumor development and progression (16, 33, 34) . Thus, the potent tumor regression could also be attributed to AR antagonism in lung cancer, which may further provide an opportunity to revisit the unsolved molecular mechanism of insoluble ES.
In light of earlier preclinical and clinical studies demonstrating that high doses of ES with sustained administration is crucial for the tumor response (10-13), our results also indicated that a 5-to 10-fold higher concentration of ES is required for suppressing PCa cell growth, compared with IC 50 on human umbilical vein endothelial cell (HUVEC) proliferation (Fig. 1A and Fig. S1 ). This observation further suggests that the mechanism of endostatin action may be different between HUVEC and PCa cells. Given the molecular action of ES targeting AR function, our results suggest that intracellular trafficking and cytosolic augmentation of ES may necessitate a high concentration of ES for inhibiting PCa cell proliferation (Fig. S7A) . When exogenous supply of ES was stopped, we also found that intracellularly accumulated ES was cleared within 24 h in ES-treated LNCaP cells (Fig. S7B) . This observation further supports our previous in vivo studies, indicating that the sustained systemic level of ES was more effective in exerting antitumor effects in a progressively developing mouse PCa model (15) . With a short halflife of purified protein that requires high quantity of administration, a constant supply of ES through gene transfer would thus be an ideal approach to overcome the limitations.
The present study provides new insight into ES as an endogenous AR inhibitor whose antagonistic action could be used for suppressing CRPC. In addition, the intrinsic function of ES as an inhibitor of tumor-associated angiogenesis can synergize with the antitumor effects when applied to AR-associated malignancy. Therefore, pleiotropic anticancer activity of ES and its proven safety in clinical trials (11) could be incorporated in chemotherapy regimens as an adjuvant to reduce possibly the risk of developing chemotherapy-induced side effects by lowering drug dose. In this respect, the combination of ES with other ARtargeted chemotherapeutics using different target sites (i.e., antiandrogens) or different molecular mechanisms (i.e., taxanes) may be of particular interest. Further, the potential of ES binding to the common AR mutation (F876L) that arises as a survival mechanism to AR-targeted therapies (1, 6, 30) would greatly increase its utility in patients with CRPC. Recent studies also demonstrated that overexpression of glucocorticoid receptor (GR) up-regulates a number of AR target genes as a mechanism of developing resistance to enzalutamide (3, 35) . Interestingly, AF-2 coactivator binding interface, the putative ES-binding site identified in this study, is structurally conserved between AR and GR (20, 36) . Therefore, these observations further provide a great opportunity to explore the possibility of ES, targeting the compensatory action of GR upon AR antagonism. Further in vivo validation in line with our previous studies on the potential of ES and results of the present study should enable translating this novel AR-targeted therapy for CRPC.
Materials and Methods
Preparation of native and mutant forms of ES is described in SI Materials and Methods. A detailed description of structural modeling of the ES/AR-LBD complex, binding assays (His-tag pull-down, coimmunoprecipitation, native-PAGE, and size-exclusion chromatography), yeast-two hybridization, and in vitro experiments (cell culture assays, immunocytochemistry, and molecular analyses) can also be found in SI Materials and Methods.
